File HF4881 ("Eliminates drug pricing council, modifies health insurance rules") is before the Minnesota Legislature and has not been decided. Latest step (April 9, 2026): Introduction and first reading, referred to.
Minnesota file HF4881, before the Minnesota Legislature. Still to be decided as of 2026-04-09.
Drug price review process ends in Minnesota The state's Prescription Drug Affordability Advisory Council, which analyzed and reported on drug pricing trends, will be eliminated, removing a state mechanism for public oversight of pharmaceutical costs.
Financial institution and health plan rules consolidated The bill modifies oversight of nondepository financial institutions and aligns health plan regulatory requirements, potentially streamlining state regulatory frameworks but shifting responsibility among agencies.
Loss of public drug pricing transparency and advocacy Without the advisory council, Minnesota residents lose a dedicated state body that tracked drug affordability issues and could advocate for price restraint, though federal and market mechanisms remain.
Prescription Drug Affordability Advisory Council eliminated, nondepository financial institution provisions modified, health plan regulatory alignment provided, duties transferred, premium security plan modified, appropriations reduced, and money appropriated.
Read the official record for HF4881
See everything up for a vote · This week in Minnesota · See what we have filed with the clerk